Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
- DOI
- 10.1093/ibd/izae024
- Published
- 2024 Dec 5
- Container
- Inflammatory bowel diseases
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/ibd/izae024,
title = {Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.},
author = {Sands BE and D'Haens G and Clemow DB and Irving PM and Johns JT and Hunter Gibble T and Abreu MT and Lee S and Hisamatsu T and Kobayashi T and Dubinsky MC and Vermeire S and Siegel CA and Peyrin-Biroulet L and Moses RE and Milata J and Arora V and Panaccione R and Dignass A},
year = {2024},
journal = {Inflammatory bowel diseases},
doi = {10.1093/ibd/izae024},
url = {https://doi.org/10.1093/ibd/izae024}
}RIS
TY - JOUR TI - Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. AU - Sands BE AU - D'Haens G AU - Clemow DB AU - Irving PM AU - Johns JT AU - Hunter Gibble T AU - Abreu MT AU - Lee S AU - Hisamatsu T AU - Kobayashi T AU - Dubinsky MC AU - Vermeire S AU - Siegel CA AU - Peyrin-Biroulet L AU - Moses RE AU - Milata J AU - Arora V AU - Panaccione R AU - Dignass A PY - 2024 JO - Inflammatory bowel diseases DO - 10.1093/ibd/izae024 UR - https://doi.org/10.1093/ibd/izae024 ER -
APA
BE, S., G, D., DB, C., PM, I., JT, J., T, H. G., MT, A., S, L., T, H., T, K., MC, D., S, V., CA, S., L, P., RE, M., J, M., V, A., R, P., & A, D. (2024). Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.. Inflammatory bowel diseases. https://doi.org/10.1093/ibd/izae024
Source records
- pubmed · retrieved 2026-09-26T17:33:47.803Z